We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NFX Nuformix Plc

0.00 (0.0%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.2725 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
0.25 0.295
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 50k -1.11M -0.0016 -1.69 1.92M
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.2725 GBX

Nuformix (NFX) Latest News

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
28/11/202319:49NUFORMIX September 2 Presentations - Massive Upside NFX298
18/5/202306:08Nuformix plc9,116

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-11-29 13:02:100.30150,000442.50O
2023-11-29 12:00:210.27550,0001,485.00AT
2023-11-29 12:00:130.27485,0001,297.86O
2023-11-29 10:49:060.27190,000508.44O

Nuformix (NFX) Top Chat Posts

Top Posts
Posted at 29/11/2023 08:20 by Nuformix Daily Update
Nuformix Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 0.27p.
Nuformix currently has 709,309,368 shares in issue. The market capitalisation of Nuformix is £1,915,135.
Nuformix has a price to earnings ratio (PE ratio) of -1.69.
This morning NFX shares opened at -
Posted at 18/9/2023 14:19 by for fx sake
Why don't you try reading it?"Under the revised agreement with, Oxilio will acquire ownership of Nuformix's NXP001 patent estate, with Nuformix receiving the additional milestone payments referred to above, whilst retaining further development milestones and royalties capped at GBP2 million per year."The keywords there are 'whilst retaining'. Meaning no change to existing capped royalties at 2m per year. The royalties will not be paid until the product goes to market and that will be years away. What's more, we have no idea how much revenue Oxilio has to make in order to pay us 2m. It might require 2bn a year, for all we know.The only thing of interest is the milestones we receive for the patent and only Oxilio and the NFX board know what they are worth. Alarm bells should ringing as to why they refuse to disclose them.
Posted at 18/9/2023 12:23 by peverill
At least this gives NFX some breathing space in any further negotiations,nothing worse for a company having to go into negotiations running on empty and no bargaining power.The fact we don't know the upfront element is disappointing,but it is what it is for the time being.Hopefully Dan an address bit more in the interview.
Posted at 18/9/2023 07:48 by peverill
But the fact they have money at all should move the price given the money situation.MM's crooked as usual.
Posted at 18/9/2023 07:26 by leadersoffice
No posts ? No move on share price? There have been some buys but wondering if this is being kept from not moving
Posted at 12/9/2023 11:19 by soupdragon55
Anne's got a funny way of signing her name on her letter.
Posted at 12/9/2023 07:44 by amaretto1
But remember she wrote a letter reassuring the markets when she left On the value of Nx2 Her opinion has not changed. EVG when it sighed a similar deal went up 400 percent in a day NFX could clearly substantially re rate on any deal Especially coming from such a low base.The company is a long way further down the road than it was back then
Posted at 08/9/2023 13:06 by peverill
Very quiet given the ERS conference starts tomorrow and a new IPF patent was published a few days ago,are the stars aligning at the right time,plus Boston conference in a few weeks with some NFX related work on show.
Posted at 20/6/2022 15:55 by pwhite73
The first sentence proves my very point.

"The payment for the shares (£1.65m gross less legal fees) is paid to Nuformix but pledged to Lanstead"

So the proceeds from the subscription is physically and financially paid to Nuformix. Nuformix then only "pledge" the money back to Lanstead depending on the share price. There is no shortfall in funds for Nuformix.

If the share price is only 0.27p and the placing price was 1.5p it means NFX will only receive £300k of the £1.65m proceeds assuming the price does not drop further if Lanstead were holding the cash from the placings.

As I said these RNSes are designed to trick you into thinking the death spiral funder has an interest in the progress of company. Its also important to note no further shares will be issued to make up for any shortfall in the share price.
Posted at 14/12/2021 17:53 by sentiment riles
Lanstead Investment – Q&A
Q. Why did Nuformix choose the Sharing Agreements with Lanstead?
A: The sharing agreements with Lanstead allows Nuformix to benefit from positive share price
performance over 20 months and the funding supports Nuformix’s activities over that period. We
see a number of positive catalysts for Nuformix over the coming months, in particular as we make
NXP004 Phase 1 ready and continue to strengthen the IP around NXP004, which should be
positive for the share price as these are announced.
Q: Is Lanstead entitled to invest monthly at a fixed discount to the prevailing Nuformix
share price from month-to-month?
A: No. Lanstead will be issued and will immediately pay for the shares it subscribes for at 1.5p
per share. The number of shares issued to Lanstead is fixed and does not change. However, the
amount from Lanstead due to the Company under the sharing agreements is adjustable upwards
or downwards at each of the 20 monthly settlements that follow. For example; the approximate
amount in any particular month will be 10% more than £82,500 if the share price is 10% higher
than the 2.0p benchmark price (“BMP”) or 10% less than £82,500 if the share price is 10% lower
than the BMP.
Q: Can Lanstead benefit by the share price being lower than the 2.0p BMP, rather than
going higher than 2.0p?
A: No. Lanstead makes more money the higher the share price is. Through the sharing
agreements Lanstead shares some, but not all, of the upside when the share price appreciates
with Nuformix. The sharing agreements are an incentive for Nuformix to perform, thereby
benefitting all shareholders including Lanstead.
If the share price over 20 months averages double the BMP (i.e. 4.0p) then the Company will
receive double the initial Lanstead subscription of £1.65 million (i.e. £3.30 million instead of £1.65
million). If the share price over 20 months averages half the BMP (i.e. 1.0p) then the Company
will ultimately receive half the initial Lanstead subscription (i.e. £0.825 million instead of £1.65
The projected outcome for Nuformix is contractually clear and the value of Lanstead’s
investment is greater if the company’s share price is higher.
It is important to note that Lanstead participates in the majority, but not all of the upside in any
future Nuformix share price appreciation. The bottom line is that Lanstead makes more money as
the share price rises and does not derive any advantage from a decline in the share price.
Q: Can Lanstead trade its Nuformix shares?
A: Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its
investee companies. Like any institutional investor Lanstead only invests in companies where it
can see strong potential for share price appreciation.
Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose
movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead
has an uncapped commitment through the sharing agreements to remit amounts each month to
Nuformix based on the prevailing share price. Therefore whilst Lanstead may take a profit along
the way (like any shareholder) and cover its downside risk on the investment (just like any
shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant
on-going shareholding because of its uncapped exposure on the amounts due to Nuformix over
the 20 months of the sharing agreements should the Nuformix shares appreciate
Posted at 21/10/2021 10:32 by inipvestor
Nuformix PLC (LON: NFX) share price surged 12.7% despite the pharmaceutical company not making significant announcements today. Here's why.The lack of news from the company indicates that today's move higher was primarily driven by buying pressure from investors and positive sentiment. The last significant announcement from Nuformix was in September when it signed an exclusive licensing deal with Oxilio Ltd to develop and commercialise its cancer drug.While there is no direct trigger behind today's rally, we know that the one single driver behind a rallying share price is buying pressure.Therefore, we can confidently say that a wave of buying pressure has hit Nuformix share, triggering the rally.The buying pressure could be from a single institutional investor accumulating a significant position in the pharma company, or it could be from a group of investors with a bullish view of the stock.From a technical analysis standpoint, Nuformix shares have pushed back above the crucial 1.30p resistance level that could now act as support.However, we would need to see further gains before saying that the resistance level has turned into support. Currently, we could see the price fail to hold above the level leading to a further decline.Investors interested in opening new bullish positions in the stock should wait for the price to hold above the support zone and retest it before jumping in.People Who Read This Also ReadSensyne Health Share Price Trades Sideways Despite EU Regulatory ApprovalCeres Power Share Price Edged Higher After Appointing a New CFOPhoenix Copper Share Price Climbs As ADR's to Begin US Tr
Nuformix share price data is direct from the London Stock Exchange

Your Recent History

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |